Ruxolitinib phosphate tablet（Jakavi,NOVARTIS,9104733)
Small molecule
Ruxolitinib phosphate tablet（Jakavi,NOVARTIS,9104733) is one of 57 small molecule programs targeting Myelofibrosis. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
139 competitors in Myelofibrosis
#DrugCompanyPhaseTrials
1Ojjaara
GGlaxo Dba Glaxosmithkline
Phase 3
Vonjo
OOrsoBio, Inc
Phase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Rytelo
GGeron Corporation
Phase 3
Best Available Therapy
NovartisPhase 3
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Navitoclax
AbbViePhase 3
Cellcept
RochePhase 2
Fludara
SanofiPhase 2
Fludara
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]